Vol. 25 No. 8

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

Jorge J. Nieva, MD, details the role of telemedicine for patients with non–small cell lung cancer and a first-of-its-kind study examining atezolizumab given subcutaneously at home.

A panel of expert clinicians discuss the treatment landscape of HER2-mutant non–small cell lung cancer, highlighting the current roles of ADCs and TKIs, and unmet needs that remain in the space.

Defining the goals of a clinical team within a cancer program or oncology practice group, where the focus will be on maximizing QOL, may be difficult.

Zyed Nabeel Zafar, MD, MPH, explores the nuances of postoperative considerations in pancreatic cancer treatment.

Stephen V. Liu, MD, details the phase 1/2 ARROS-1 study evaluating the selective ROS1 inhibitor zidesamtinib in patients with ROS1 fusion–positive non–small cell lung cancer.

Joyce F. Liu, MD, MPH, provides insights on WEE1 which has emerged as a potentially targetable pathway in high-grade serous ovarian cancer.